AINGENS, a life sciences software company, is using AI to reduce 'scientific friction' in the industry. Founder Ome Ogbru, PharmD, says the problem is not a lack of intelligence, but how the work gets done. The company's platform, MACG (Medical Affairs Content Generator), uses generative AI to automate mundane tasks such as literature search, drafting, and formatting, while human experts apply regulatory knowledge, scientific context, and guardrails to keep content accurate and compliant.
Overview
Life sciences teams still spend months procuring clunky systems, and highly trained experts are buried in literature searches and manual drafting. AINGENS' platform is designed to change that by pairing AI with deep domain expertise and workflows built for real scientific work.
What it does
The MACG platform handles time-consuming tasks, allowing human experts to focus on scientific judgment, strategy, and communication. It is designed to improve the speed and accuracy of medical and scientific communication without compromising accuracy or compliance.
Tradeoffs
While generative AI is not the answer by itself, pairing it with human expertise and workflows can lead to significant improvements in productivity and accuracy. However, it requires a deep understanding of the pain points experts face and the ability to deploy AI as a tool, not as a replacement for judgment.
In conclusion, AINGENS' use of AI to streamline life sciences workflows has the potential to accelerate drug discovery timelines and improve the accuracy of medical and scientific communication. By pairing AI with human expertise and workflows, the company is helping to reduce 'scientific friction' and free up experts to focus on high-value tasks.